First Horizon Corp Invests $570,000 in Boston Scientific Corporation $BSX

First Horizon Corp bought a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 5,841 shares of the medical equipment provider’s stock, valued at approximately $570,000.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Boston Scientific by 136.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,423 shares of the medical equipment provider’s stock valued at $345,000 after purchasing an additional 1,977 shares during the last quarter. Modern Wealth Management LLC boosted its position in Boston Scientific by 7.9% during the first quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 218 shares during the period. Parallel Advisors LLC increased its holdings in shares of Boston Scientific by 5.9% in the second quarter. Parallel Advisors LLC now owns 16,370 shares of the medical equipment provider’s stock valued at $1,758,000 after purchasing an additional 911 shares during the last quarter. Finally, NBC Securities Inc. raised its position in shares of Boston Scientific by 3.9% in the second quarter. NBC Securities Inc. now owns 12,598 shares of the medical equipment provider’s stock valued at $1,353,000 after purchasing an additional 472 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $94.02 on Wednesday. The business has a fifty day moving average price of $97.43 and a two-hundred day moving average price of $100.58. The stock has a market capitalization of $139.37 billion, a PE ratio of 50.28, a P/E/G ratio of 1.69 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on BSX shares. Morgan Stanley upped their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Canaccord Genuity Group decreased their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Evercore ISI set a $112.00 price target on Boston Scientific in a report on Monday, January 5th. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Finally, Royal Bank Of Canada increased their price objective on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $125.21.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint PFA catheter expands BSX’s electrophysiology portfolio and supports procedure-driven recurring revenue; regulatory win should accelerate commercial roll‑out in atrial fibrillation ablation. Article Title
• Positive Sentiment: Agreement to acquire Valencia Technologies broadens BSX’s pelvic/uroLOGY offering for urinary incontinence and overactive bladder — gives exposure to a high-growth segment and supports the company’s stated pelvic-health strategy. (Official release) Article Title
• Positive Sentiment: J.P. Morgan coverage/notes highlight expectations for strong PFA performance in 2026 and beyond, reinforcing growth prospects for BSX’s higher‑margin electrophysiology portfolio. Article Title
• Positive Sentiment: Bank of America (analyst Travis Steed) reaffirmed a Buy rating and a $120 price target, citing strategic pelvic‑health expansion and the Valencia deal as upside drivers. Article Title
• Positive Sentiment: Sector write‑ups note BSX is benefiting from favorable product‑mix shifts toward higher‑margin devices, supporting margin expansion and durable revenue growth. Article Title
• Neutral Sentiment: Management’s JP Morgan conference presentation/transcript provides updated strategic context and reinforcement of guidance, useful for modeling but not a discrete catalyst by itself. Article Title
• Negative Sentiment: Short‑term sell pressure: some coverage noted the stock fell despite a strong market day and higher volume — suggesting profit‑taking, rotation away from richly valued medtech names (BSX’s trailing P/E is elevated) may be weighing on the share price. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.